How OHSU could help validate a promising new Parkinson's therapy

The phase 1 clinical trial involved an antibody targeting the alpha-synuclein protein, which scientists believe causes specific brain cells to die in patients with Parkinson ’s disease, which affects 1.5 million people in the U.S.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 18, 2018 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news